Belgium UCLouvain Louvain Drug Research Institute (LDRI) and Netherlands MedTech Start-up Gilbert join efforts for improved therapy for Cystic Fibrosis Patients.
LDRI receives funding for the development of a long-acting PEGylated rhDNase for CF-treatment with reduced therapeutic burden.
Click here for the full text press release.
MedTech Magazine, December 2018
When it comes to pulmonary drug administration and therapy adherence, it is noted that many of the commercially available inhalers such as Dry Powder Inhalers (DPIs) and Metered Dose Inhalers (MDIs) are relatively limited in their effectiveness. In this article, Maurits Huigen explains why and how Gilbert solves the limiting effects of current inhalers with a new finding using an electrospraying technique.
Read the full article published on Med Tech Outlook.